Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway

[D.ap]

“Learn about the PD-1/PD-L1 checkpoint pathway, its function in cancer, and how it is being used in immunotherapy.
What is the PD-1/PD-L1 pathway?
The PD-1 (programmed cell death-1) receptor (also known as CD279) is expressed on the surface of activated T cells. Its ligands, PD-L1 (B7-H1; CD274) and PD-L2 (B7-DC; CD273), are commonly expressed on the surface of dendritic cells or macrophages. PD-1 and PD-L1/PD-L2 belong to the family of immune checkpoint proteins that act as co-inhibitory factors, which can halt or limit the development of the T cell response. PD-1/PD-L1 interaction ensures that the immune system is activated only at the appropriate time in order to minimize the possibility of chronic autoimmune inflammation.”

http://www.abcam.com/cancer/cancer-immu ... l1-pathway